Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Smith

Showing results (151-160 of 188) with videos related to

Pageof 19
Sort By:
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Leukemia|February 15, 2019
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemiaNicole A McNeer, John Philip, Heather Geiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2017
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid LeukemiaEmilia L Lim, Diane L Trinh, Rhonda E Ries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription FactorChristy L Osgood, Nichole Maloney, Christopher G Kidd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Plos One|January 26, 2016
The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample SetsHumaira Rasheed, Cushla McKinney, Lisa K Stamp, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupAmi V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Neuro-Oncology|February 25, 2021
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium studyJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
JAK mutations in high-risk childhood acute lymphoblastic leukemiaCharles G Mullighan, Jinghui Zhang, Richard C Harvey, et al.
Pageof 19

Showing results (151-160 of 188) with videos related to

Sort By:
Pageof 19
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Leukemia|February 15, 2019
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemiaNicole A McNeer, John Philip, Heather Geiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2017
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid LeukemiaEmilia L Lim, Diane L Trinh, Rhonda E Ries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription FactorChristy L Osgood, Nichole Maloney, Christopher G Kidd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Plos One|January 26, 2016
The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample SetsHumaira Rasheed, Cushla McKinney, Lisa K Stamp, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupAmi V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Neuro-Oncology|February 25, 2021
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium studyJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
JAK mutations in high-risk childhood acute lymphoblastic leukemiaCharles G Mullighan, Jinghui Zhang, Richard C Harvey, et al.
Pageof 19